Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study
BackgroundDespite the availability of vaccines, immunocompromised patients are still at high risk for severe COVID-19. Vaccination has been proven to be an effective measure in preventing severe SARS-CoV-2 infections; however, data on B- and T-cell responses are lacking. Whil...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2025-05-01
|
| Series: | JMIR Research Protocols |
| Online Access: | https://www.researchprotocols.org/2025/1/e60675 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850141276332097536 |
|---|---|
| author | Louise Marie Cremer Ullrich Bethe Peter Borchmann Veronica Di Cristanziano Lutz Gieselmann Sarah Grimm Martin Hellmich Julia Jakobs Julia A Nacov Julia M Neuhann Juergen Prattes Christoph Scheid Rosanne Sprute Gertrud Steger Jannik Stemler Sibylle C Mellinghoff Oliver A Cornely |
| author_facet | Louise Marie Cremer Ullrich Bethe Peter Borchmann Veronica Di Cristanziano Lutz Gieselmann Sarah Grimm Martin Hellmich Julia Jakobs Julia A Nacov Julia M Neuhann Juergen Prattes Christoph Scheid Rosanne Sprute Gertrud Steger Jannik Stemler Sibylle C Mellinghoff Oliver A Cornely |
| author_sort | Louise Marie Cremer |
| collection | DOAJ |
| description |
BackgroundDespite the availability of vaccines, immunocompromised patients are still at high risk for severe COVID-19. Vaccination has been proven to be an effective measure in preventing severe SARS-CoV-2 infections; however, data on B- and T-cell responses are lacking. While vaccination schedules for the general population have been defined, achieving immunogenicity in patients who are immunocompromised remains a challenge.
ObjectiveThe primary objective is to analyze anti-spike–immunoglobulin G (IgG) titers after repeated messenger ribonucleic acid vaccinations in patients who are immunocompromised. Further objectives are to analyze data on humoral immune responses and to evaluate data on cellular immune responses.
MethodsThis multicenter, prospective, noninterventional study aims to determine the immunogenicity and reactogenicity of an implemented standard-of-care COVID-19 vaccination strategy in patients who are immunocompromised. A total of 100 patients will be recruited at three study sites. Patients are eligible for study inclusion when they are 18 years or older, vaccinated according to the recent version of the COVID-19 vaccination standard, and if the patient is immunocompromised according to stage 3 of the classification “Stages of Immunosuppression.” The study analyzes B- and T-cell responses generated within the standard-of-care COVID-19 vaccination strategy. Additional blood samples will be drawn at each scheduled outpatient visit. Study-related blood samples will be used to extract ethylenediaminetetraacetic acid plasma and peripheral blood mononuclear cells for evaluation of B- and T-cell responses to COVID-19 vaccinations. For this study, no additional visits or invasive procedures will be performed in addition to standard care.
ResultsAs of August 2024, the study has enrolled 32 patients. The recruitment phase is still ongoing.
ConclusionsResults will be used to optimize vaccination and booster schedules for patients who are immunocompromised and to increase rates of protection against severe SARS-CoV-2 infections. Further, results may identify risk and treatment factors, which lead to low immune responses in patients vaccinated against COVID-19, as well as the impact of repeated vaccination on B- and T-cell responses.
Trial RegistrationClinicalTrials.gov NCT05597761; https://clinicaltrials.gov/study/NCT05597761
International Registered Report Identifier (IRRID)DERR1-10.2196/60675 |
| format | Article |
| id | doaj-art-2f4a0b45356e48d6814a36ca3a85d351 |
| institution | OA Journals |
| issn | 1929-0748 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIR Research Protocols |
| spelling | doaj-art-2f4a0b45356e48d6814a36ca3a85d3512025-08-20T02:29:30ZengJMIR PublicationsJMIR Research Protocols1929-07482025-05-0114e6067510.2196/60675Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional StudyLouise Marie Cremerhttps://orcid.org/0009-0002-1425-7352Ullrich Bethehttps://orcid.org/0000-0001-9979-1671Peter Borchmannhttps://orcid.org/0000-0003-3782-2158Veronica Di Cristanzianohttps://orcid.org/0000-0003-1604-8386Lutz Gieselmannhttps://orcid.org/0000-0003-3699-3318Sarah Grimmhttps://orcid.org/0000-0001-7680-0344Martin Hellmichhttps://orcid.org/0000-0001-5174-928XJulia Jakobshttps://orcid.org/0000-0002-4669-690XJulia A Nacovhttps://orcid.org/0000-0002-5327-2937Julia M Neuhannhttps://orcid.org/0000-0003-4479-6322Juergen Pratteshttps://orcid.org/0000-0001-5751-9311Christoph Scheidhttps://orcid.org/0009-0007-6539-226XRosanne Sprutehttps://orcid.org/0000-0003-2457-6437Gertrud Stegerhttps://orcid.org/0000-0002-0581-8122Jannik Stemlerhttps://orcid.org/0000-0001-9152-2469Sibylle C Mellinghoffhttps://orcid.org/0000-0003-3928-2503Oliver A Cornelyhttps://orcid.org/0000-0001-9599-3137 BackgroundDespite the availability of vaccines, immunocompromised patients are still at high risk for severe COVID-19. Vaccination has been proven to be an effective measure in preventing severe SARS-CoV-2 infections; however, data on B- and T-cell responses are lacking. While vaccination schedules for the general population have been defined, achieving immunogenicity in patients who are immunocompromised remains a challenge. ObjectiveThe primary objective is to analyze anti-spike–immunoglobulin G (IgG) titers after repeated messenger ribonucleic acid vaccinations in patients who are immunocompromised. Further objectives are to analyze data on humoral immune responses and to evaluate data on cellular immune responses. MethodsThis multicenter, prospective, noninterventional study aims to determine the immunogenicity and reactogenicity of an implemented standard-of-care COVID-19 vaccination strategy in patients who are immunocompromised. A total of 100 patients will be recruited at three study sites. Patients are eligible for study inclusion when they are 18 years or older, vaccinated according to the recent version of the COVID-19 vaccination standard, and if the patient is immunocompromised according to stage 3 of the classification “Stages of Immunosuppression.” The study analyzes B- and T-cell responses generated within the standard-of-care COVID-19 vaccination strategy. Additional blood samples will be drawn at each scheduled outpatient visit. Study-related blood samples will be used to extract ethylenediaminetetraacetic acid plasma and peripheral blood mononuclear cells for evaluation of B- and T-cell responses to COVID-19 vaccinations. For this study, no additional visits or invasive procedures will be performed in addition to standard care. ResultsAs of August 2024, the study has enrolled 32 patients. The recruitment phase is still ongoing. ConclusionsResults will be used to optimize vaccination and booster schedules for patients who are immunocompromised and to increase rates of protection against severe SARS-CoV-2 infections. Further, results may identify risk and treatment factors, which lead to low immune responses in patients vaccinated against COVID-19, as well as the impact of repeated vaccination on B- and T-cell responses. Trial RegistrationClinicalTrials.gov NCT05597761; https://clinicaltrials.gov/study/NCT05597761 International Registered Report Identifier (IRRID)DERR1-10.2196/60675https://www.researchprotocols.org/2025/1/e60675 |
| spellingShingle | Louise Marie Cremer Ullrich Bethe Peter Borchmann Veronica Di Cristanziano Lutz Gieselmann Sarah Grimm Martin Hellmich Julia Jakobs Julia A Nacov Julia M Neuhann Juergen Prattes Christoph Scheid Rosanne Sprute Gertrud Steger Jannik Stemler Sibylle C Mellinghoff Oliver A Cornely Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study JMIR Research Protocols |
| title | Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study |
| title_full | Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study |
| title_fullStr | Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study |
| title_full_unstemmed | Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study |
| title_short | Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study |
| title_sort | immunogenicity of covid 19 vaccination in immunocompromised patients auto covid vacc protocol for multicenter prospective noninterventional study |
| url | https://www.researchprotocols.org/2025/1/e60675 |
| work_keys_str_mv | AT louisemariecremer immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT ullrichbethe immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT peterborchmann immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT veronicadicristanziano immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT lutzgieselmann immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT sarahgrimm immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT martinhellmich immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT juliajakobs immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT juliaanacov immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT juliamneuhann immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT juergenprattes immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT christophscheid immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT rosannesprute immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT gertrudsteger immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT jannikstemler immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT sibyllecmellinghoff immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy AT oliveracornely immunogenicityofcovid19vaccinationinimmunocompromisedpatientsautocovidvaccprotocolformulticenterprospectivenoninterventionalstudy |